ClinicalTrials.gg
TerminatedNCT00879970TIDEUpdated Apr 18, 2017Results posted

Thiazolidinedione Intervention With Vitamin D Evaluation

A Phase 4 interventional study of pioglitazone and rosiglitazone in Diabetes Mellitus, Type 2, sponsored by GlaxoSmithKline. Terminated at 331 sites in 25 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2017-04-18.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Why this study was terminated
FDA has placed the trial on full clinical hold.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,332
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 — 7 open to participants now, 8 under way, 1 of them phase 3. Pioglitazone · Diabetes Mellitus, Type 2.

Enrollment
7th of 122
1,332 · median 103
Started
2009
with 6 others
Phase 4
57 of 122
4 open now
Registered
60th of 122
by date
Lead sponsor
2 of 122
GlaxoSmithKline

Among the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, this one is the 7th largest by enrollment, is one of 7 that started in 2009, is one of 57 in phase 4, and was the 60th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

7 of the 122 studies testing pioglitazone in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About pioglitazone

Pioglitazone: first FDA approval 1999 (ACTOS), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies testing pioglitazone in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will answer two separate questions.

The first question is to test the cardiovascular effects of long-term treatment with rosiglitazone or pioglitazone when used as part of standard of care compared to similar standard of care without rosiglitazone or pioglitazone in patients with type 2 diabetes who have a history of or are at risk for cardiovascular disease.

The second question will compare the effects of long-term supplementation of vitamin D on death and cancer

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Cardiovascular Outcomes
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women with: a) newly detected type 2 diabetes based on a fasting plasma glucose greater than or equal to 7.0 mmol/l (126 mg/dL) or a 2 hour plasma glucose (FPG) greater than or equal to 11.1 mmol/l (200 mg/dL) on an oral glucose tolerance test, or b) a history of type 2 diabetes
  • (A1C) 6.5-9.5% inclusive (for assays with of 6%) within one month of screening
  • Age ≥ 50 years and evidence of vascular disease defined as ≥1of:

    • prior myocardial infarction
    • prior stroke
    • coronary, carotid or peripheral artery revascularization ≥ 4 years earlier
    • previous documented myocardial ischemia on either an exercise stress test or on any cardiac imaging, or previous unstable angina with changes or cardiac enzyme elevation OR
  • Age ≥ 55 years and evidence of subclinical vascular disease defined as ≥1 of:

    • microalbuminuria or proteinuria
    • history of treated or untreated hypertension with left ventricular hypertrophy by electrocardiogram (ECG) or echocardiogram

      • 50% stenosis on any imaging of coronary, carotid or lower extremity arteries
    • ankle/brachial index \<0.9 OR
  • Age ≥ 60 years and at least 2 of the following cardiovascular disease risk factors:

    • current tobacco use
    • LDL-c ≥3.4 mmol/L (130 mg/dL) or on a lipid lowering medication
    • HDL-c \< 1.0 mmol/L (40 mg/dL) for men and \< 1.3 mmol/L (50 mg/dL) for women or triglycerides ≥ 2.3 mmol/L (200 mg/dL)
    • BP lowering medication use or untreated SBP ≥ 140 mmHg or DBP ≥ 95 mmHg
    • Waist to hip ratio > 1.0 for men and > 0.8 for women
  • On no insulin and on less than or equal to 2 anti-diabetes drugs where at least one drug is at or below the half-maximal dose (as indicated in the MOP) with stable dosing for 10 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Current need for insulin treatment
  • Symptomatic hyperglycemia requiring immediate therapy in the judgment of the physician
  • An acute cardiovascular event within 30 days prior to randomization
  • Symptomatic heart failure (i.e. class II or higher) or any episode of previous pulmonary edema or known \< 0.4 or current use of loop diuretics
  • Any fracture within the past 1 year
  • Currently planned coronary, carotid or peripheral artery revascularization or cardiac valve surgery
  • Coronary, carotid or peripheral artery revascularization within the 4 years prior to screening in the absence of angina, MI, or stroke in the intervening period
  • End stage renal disease requiring renal replacement therapy
  • Receiving drug therapy to treat liver disease
  • A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer (other than prophylactic)
  • (ALT) or aspartate aminotransferase (AST) level > 2.5 times the
  • A prior heart transplant or awaiting a heart transplant
  • Previous or current hypercalcemia, hyperparathyroidism, osteomalacia or other for vitamin D therapy
  • Regular use of or indication for greater than 400IU of vitamin D daily
  • Clinically or medically unstable with expected survival \< 1 year
  • Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant's data
  • Any other factor likely to limit protocol compliance or reporting of adverse events
  • Inability to discontinue a TZD (if taking one) in the judgement of the physician/investigator
  • Contraindications to or history of to the products
  • History of renal stones within the past 2 years
  • Participation in another clinical trial of an investigational agent
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,332 participants (actual)

Study arms

  • Active comparator
    pioglitazone

    PIO tablet was administered in the dose of 30 milligrams (mg) OD initially and could be titrated to a maximum dose of 45 mg at or after the 6-month visit. After 1 year of treatment, the dose of PIO was increased to 45 mg OD for the duration of 5.5 years.

    Drug: pioglitazone

  • Active comparator
    rosiglitazone

    RSG tablet was administered in the dose of 4 mg OD initially and could be titrated to a maximum dose of 8 mg at or after the 6-month visit. After 1 year of treatment, the dose of RSG was increased to 8 mg OD for the duration of 5.5 years.

    Drug: rosiglitazone

  • Placebo comparator
    TZD placebo

    Matching placebo tablet was administered once a day (OD) for the duration of 5.5 years

    Drug: placebo

  • Active comparator
    Vitamin D

    Active comparator

    Dietary Supplement: Vitamin D

  • Placebo comparator
    Vitamin D placebo

    Placebo Comparator

    Dietary Supplement: Placebo

Interventions

  • Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.

  • Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.

  • Drugplacebo

    Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.

  • Dietary supplementVitamin D

    Vitamin D factor intervention

  • Dietary supplementPlacebo

    Vitamin D factor intervention

06

What researchers measure

Primary outcomes

  1. Number of Participants With the Indicated Components of the Composite Cardiovascular Outcome for Thiazolidinedione (TZD)

    An event adjudication committee (EAC) adjudicated all occurrences of the components of the composite cardiovascular (CV; related to heart) outcome for TZD. Components are the first occurrence of cardiovascular death for which a non-heart-related cause has not been identified; non-fatal myocardial infarction (MI) (death of heart muscle from sudden blockage of a coronary artery by blood clot not leading to death); and non-fatal stroke (rapidly developing loss of brain function\[s\] due to disturbance in the blood supply to the brain not leading to death).

    Time frame: From Randomization at Visit 3 up to the Final Visit (average of 162 days)

  2. Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D

    An EAC adjudicated all occurrences of the components of the composite outcome for vitamin D. Components are the first occurrence of death or cancer requiring hospitalization, treatment with medicines (chemotherapy), or surgery.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

Secondary outcomes

  1. Number of Participants With Any Revascularization

    Revascularization is defined as any surgical procedure for the provision of a new, additional, or augmented blood supply to heart muscle. Data regarding the need for any revascularization were adjudicated by the EAC and sent to the data monitoring committee (IDMC) on a regular basis for unblinded review.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  2. Number of Participants With Need for Hospitalization for Any Reason

    Data regarding the need for hospitalization for any reason were collected and were then forwarded to the independent data monitoring committee (IDMC) on a regular basis for unblinded review.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  3. Number of Participants With Need for Hospitalization for Congestive Heart Failure (CHF), Shortness of Breath, Pneumonia, or Angina

    CHF is a condition in which the heart is not able to pump adequate blood to meet the body's needs. Shortness of breath is defined as difficulty in breathing. Pneumonia is an infection of the lungs, caused by various microorganisms. Angina is defined as severe chest pain due to lack of adequate blood supply of the heart muscle because of obstruction/spasm of the heart's blood vessels. Data regarding the need for hospitalization due to any of these reasons were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  4. Number of Participants With Composite Microvascular Outcome

    The components of the composite microvascular outcome are retinopathy, decline in eGFR, vitrectomy, and renal replacement surgery. Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data regarding the number of participants with changes in micro blood vessels (composite microvascular outcome) were collected at each visit.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  5. Number of Participants With Retinopathy Requiring Laser Therapy, a Decline in Estimated Glomerular Filtration Rate (eGFR), Vitrectomy, and Renal Replacement Therapy

    Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data on the number of participants with all of these microvascular outcomes were collected at each visit. Data regarding the number of participants with these microvascular outcomes were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  6. Number of Participants With Severe Lower Than Normal Blood Glucose Level (Hypoglycemia)

    Severe hypoglycemia is defined as hypoglycemia requiring assistance from another person with either a documented plasma glucose \<=36 mg/deciliter (2.0 millimole per liter \[mmol/L\]) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. Hypoglycemia data were obtained from outcomes reported by the site. Data regarding hypoglycemia were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  7. Number of Participants With Clinical Proteinuria

    Clinical proteinuria is defined as a laboratory detection of urinary protein excretion \> 0.5 grams (g) per 24 hours; spot urine analysis for albumin:creatinine ratio \>=300 milligrams/g; timed urine collection for albumin excretion \>=200 µg/minute or \>=300 mg/24 hours. Clinical proteinuria data were obtained from outcomes reported by the site.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  8. Number of Participants With a Fracture

    Fracture is defined as a medical condition in which there is a break in the continuity of the bone. Fractures are defined as those breaks that are self reported plus confirmed by an X-ray. Data regarding all occurrences of any fracture were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  9. Number of Participants With Hepatic Enzyme Increased or Abnormal Liver Function Tests

    Liver function tests are groups of clinical biochemistry laboratory blood assays designed to give information about the health of the liver. "Liver function test abnormal" and "hepatic enzyme increased" were obtained from adverse event data as reported by investigators based on the reference range of the reporting local laboratory methodology. The vitamin D arm was not analyzed for this outcome measure.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  10. Number of Participants With Cognitive (Mental Processes) Decline (CD) From Baseline to the Year 2 Visit and the Final Visit

    CD is equivalent to a difference of \>=1.5 units on the Digit Symbol Substitution Test (DSST) score. The DSST is a neuropsychological test sensitive to brain damage, a serious loss of cognitive ability, age, and depression. It consists of digit-symbol pairs, followed by a list of digits. Under each digit the participant was asked to write the corresponding symbol as quickly as possible. The number of correct symbols within the allowed time (90 or 120 seconds) was measured in units (one correct score equals one unit).

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  11. Number of Participants With Erectile Dysfunction

    Erectile dysfunction (ED) is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance. ED was assessed by using the International Index of Erectile Dysfunction (IIED) questionnaire. This standardized and validated 15-item self-evaluation scale provides pre- and post-treatment clinic evaluations of erectile and orgasmic function, sexual desire, satisfaction with sexual intercourse, and general satisfaction.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  12. Mean Score on Euro-QoL (EQ)-5D

    Quality of life (QoL) was assessed by using the Euro-QoL (EQ)-5D, a short questionnaire used for measuring health-related QoL. The preference weights are elicited by asking participants to place hypothetical health states on a visual analogue scale from "0" to "1", whereby a score of "1" represents the best health state imaginable and "0" represents a health state equivalent to being dead. Negative states are those worse than being dead.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

  13. Mean Score on Montreal Cognitive Assessment (MoCA) Test, as an Assessment of Cognitive Function (CF)

    CF was assessed with the 30-point (pt) MoCA test, involving a short-term memory recall task (T) (5 pts), a clock-drawing T (3 pts), a 3-dimensional cube copy (1 pt), a trail-making B T (1 pt), a phonemic fluency T (1 pt), a 2-item verbal abstraction T (2 pts), an attention T (1 pt), a serial subtraction T (3 pts), digits forward/ backward (1 pt each), a 3-item confrontation naming T (3 pts), repetition of 2 syntactically complex sentences (2 pts), and orientation to time/ place (6 pts). A score of 26 or above is normal.

    Time frame: From Randomization at Visit 3 to Final Visit (up to 162 days)

07

Results

Posted Dec 13, 2011
Limitations and caveats
The intended duration of this study was approximately 5.5 years. However, the trial was stopped prematurely because of regulatory concerns after a mean of 162 days without consideration of the accrued data.

Participant flow

1332 participants were included in the TZD randomization, and 1221 of 1332 participants were included in the Vitamin D randomization.

Period 1 TZD Randomization
Participant flow — Period 1 TZD Randomization
MilestonePlaceboPioglitazone (PIO)Rosiglitazone (RSG)Vitamin D PlaceboVitamin D
Started54139239900
Completed53338839300
Not completed84600
Withdrew: Refused to attend final visit33400
Withdrew: Lost to follow-up10100
Withdrew: Death21000
Withdrew: Final or study hold visits not completed20100
Period 2 Vitamin D Randomization
Participant flow — Period 2 Vitamin D Randomization
MilestonePlaceboPioglitazone (PIO)Rosiglitazone (RSG)Vitamin D PlaceboVitamin D
Started000614607
Completed000610600
Not completed00047
Withdrew: Refused to attend final visit00026
Withdrew: Lost to follow-up00001
Withdrew: Death00020

Outcome measures

PrimaryNumber of Participants With the Indicated Components of the Composite Cardiovascular Outcome for Thiazolidinedione (TZD)

An event adjudication committee (EAC) adjudicated all occurrences of the components of the composite cardiovascular (CV; related to heart) outcome for TZD. Components are the first occurrence of cardiovascular death for which a non-heart-related cause has not been identified; non-fatal myocardial infarction (MI) (death of heart muscle from sudden blockage of a coronary artery by blood clot not leading to death); and non-fatal stroke (rapidly developing loss of brain function\[s\] due to disturbance in the blood supply to the brain not leading to death).

Time frame:
From Randomization at Visit 3 up to the Final Visit (average of 162 days)
Reported as:
Number · participants
Number of Participants With the Indicated Components of the Composite Cardiovascular Outcome for Thiazolidinedione (TZD)
participantsPlaceboPioglitazone (PIO)Rosiglitazone (RSG)Vitamin D PlaceboVitamin D
CV Death/Non-Fatal MI/Non-Fatal Stroke52132
CV Death10010
Non-Fatal MI20111
Non-Fatal Stroke22011
PrimaryNumber of Participants With the Indicated Components of the Composite Outcome for Vitamin D

An EAC adjudicated all occurrences of the components of the composite outcome for vitamin D. Components are the first occurrence of death or cancer requiring hospitalization, treatment with medicines (chemotherapy), or surgery.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With the Indicated Components of the Composite Outcome for Vitamin D
participantsPlaceboPioglitzaoneRosiglitazoneVitamin D PlaceboVitamin D
Death or serious cancer63132
All death41120
Serious cancer22012
SecondaryNumber of Participants With Any Revascularization

Revascularization is defined as any surgical procedure for the provision of a new, additional, or augmented blood supply to heart muscle. Data regarding the need for any revascularization were adjudicated by the EAC and sent to the data monitoring committee (IDMC) on a regular basis for unblinded review.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Any Revascularization
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Number of Participants With Any Revascularization63575
SecondaryNumber of Participants With Need for Hospitalization for Any Reason

Data regarding the need for hospitalization for any reason were collected and were then forwarded to the independent data monitoring committee (IDMC) on a regular basis for unblinded review.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Need for Hospitalization for Any Reason
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Number of Participants With Need for Hospitalization for Any Reason3116241932
SecondaryNumber of Participants With Need for Hospitalization for Congestive Heart Failure (CHF), Shortness of Breath, Pneumonia, or Angina

CHF is a condition in which the heart is not able to pump adequate blood to meet the body's needs. Shortness of breath is defined as difficulty in breathing. Pneumonia is an infection of the lungs, caused by various microorganisms. Angina is defined as severe chest pain due to lack of adequate blood supply of the heart muscle because of obstruction/spasm of the heart's blood vessels. Data regarding the need for hospitalization due to any of these reasons were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Need for Hospitalization for Congestive Heart Failure (CHF), Shortness of Breath, Pneumonia, or Angina
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
CHF12002
Shortness of breath01201
Pneumonia01000
Angina311NANA
SecondaryNumber of Participants With Composite Microvascular Outcome

The components of the composite microvascular outcome are retinopathy, decline in eGFR, vitrectomy, and renal replacement surgery. Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data regarding the number of participants with changes in micro blood vessels (composite microvascular outcome) were collected at each visit.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Composite Microvascular Outcome
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Number of Participants With Composite Microvascular Outcome21891818
SecondaryNumber of Participants With Retinopathy Requiring Laser Therapy, a Decline in Estimated Glomerular Filtration Rate (eGFR), Vitrectomy, and Renal Replacement Therapy

Retinopathy is defined as damage to the inner lining of the eye (retina). Decline in eGFR is defined as a \>=30% reduction in kidney function. Vitrectomy is a surgery to remove some or all of the fluid (vitreous humor) from the eye. Renal replacement therapy includes all the life-supporting treatments for renal failure. Data on the number of participants with all of these microvascular outcomes were collected at each visit. Data regarding the number of participants with these microvascular outcomes were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Retinopathy Requiring Laser Therapy, a Decline in Estimated Glomerular Filtration Rate (eGFR), Vitrectomy, and Renal Replacement Therapy
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Retinopathy Requiring Laser Therapy10000
Decline in eGFR >=30%20891818
Vitrectomy00000
Renal Replacement Therapy00000
SecondaryNumber of Participants With Severe Lower Than Normal Blood Glucose Level (Hypoglycemia)

Severe hypoglycemia is defined as hypoglycemia requiring assistance from another person with either a documented plasma glucose \<=36 mg/deciliter (2.0 millimole per liter \[mmol/L\]) or prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration. Hypoglycemia data were obtained from outcomes reported by the site. Data regarding hypoglycemia were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Severe Lower Than Normal Blood Glucose Level (Hypoglycemia)
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Number of Participants With Severe Lower Than Normal Blood Glucose Level (Hypoglycemia)02103
SecondaryNumber of Participants With Clinical Proteinuria

Clinical proteinuria is defined as a laboratory detection of urinary protein excretion \> 0.5 grams (g) per 24 hours; spot urine analysis for albumin:creatinine ratio \>=300 milligrams/g; timed urine collection for albumin excretion \>=200 µg/minute or \>=300 mg/24 hours. Clinical proteinuria data were obtained from outcomes reported by the site.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Clinical Proteinuria
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Number of Participants With Clinical Proteinuria100NANA
SecondaryNumber of Participants With a Fracture

Fracture is defined as a medical condition in which there is a break in the continuity of the bone. Fractures are defined as those breaks that are self reported plus confirmed by an X-ray. Data regarding all occurrences of any fracture were adjudicated by the EAC and sent to the IDMC on a regular basis for unblinded review.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With a Fracture
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Number of Participants With a Fracture22333
SecondaryNumber of Participants With Hepatic Enzyme Increased or Abnormal Liver Function Tests

Liver function tests are groups of clinical biochemistry laboratory blood assays designed to give information about the health of the liver. "Liver function test abnormal" and "hepatic enzyme increased" were obtained from adverse event data as reported by investigators based on the reference range of the reporting local laboratory methodology. The vitamin D arm was not analyzed for this outcome measure.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)
Reported as:
Number · participants
Number of Participants With Hepatic Enzyme Increased or Abnormal Liver Function Tests
participantsPlaceboPioglitazoneRosiglitazoneVITAMIN D PLACEBOVITAMIN D
Number of Participants With Hepatic Enzyme Increased or Abnormal Liver Function Tests101NANA
SecondaryNumber of Participants With Cognitive (Mental Processes) Decline (CD) From Baseline to the Year 2 Visit and the Final Visit

CD is equivalent to a difference of \>=1.5 units on the Digit Symbol Substitution Test (DSST) score. The DSST is a neuropsychological test sensitive to brain damage, a serious loss of cognitive ability, age, and depression. It consists of digit-symbol pairs, followed by a list of digits. Under each digit the participant was asked to write the corresponding symbol as quickly as possible. The number of correct symbols within the allowed time (90 or 120 seconds) was measured in units (one correct score equals one unit).

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)

No measurements were reported for this outcome.

SecondaryNumber of Participants With Erectile Dysfunction

Erectile dysfunction (ED) is sexual dysfunction characterized by the inability to develop or maintain an erection of the penis during sexual performance. ED was assessed by using the International Index of Erectile Dysfunction (IIED) questionnaire. This standardized and validated 15-item self-evaluation scale provides pre- and post-treatment clinic evaluations of erectile and orgasmic function, sexual desire, satisfaction with sexual intercourse, and general satisfaction.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)

No measurements were reported for this outcome.

SecondaryMean Score on Euro-QoL (EQ)-5D

Quality of life (QoL) was assessed by using the Euro-QoL (EQ)-5D, a short questionnaire used for measuring health-related QoL. The preference weights are elicited by asking participants to place hypothetical health states on a visual analogue scale from "0" to "1", whereby a score of "1" represents the best health state imaginable and "0" represents a health state equivalent to being dead. Negative states are those worse than being dead.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)

No measurements were reported for this outcome.

SecondaryMean Score on Montreal Cognitive Assessment (MoCA) Test, as an Assessment of Cognitive Function (CF)

CF was assessed with the 30-point (pt) MoCA test, involving a short-term memory recall task (T) (5 pts), a clock-drawing T (3 pts), a 3-dimensional cube copy (1 pt), a trail-making B T (1 pt), a phonemic fluency T (1 pt), a 2-item verbal abstraction T (2 pts), an attention T (1 pt), a serial subtraction T (3 pts), digits forward/ backward (1 pt each), a 3-item confrontation naming T (3 pts), repetition of 2 syntactically complex sentences (2 pts), and orientation to time/ place (6 pts). A score of 26 or above is normal.

Time frame:
From Randomization at Visit 3 to Final Visit (up to 162 days)

No measurements were reported for this outcome.

Adverse events

Collected over 162 days for the TZD arm; 130 days for the vitamin D arm. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—7/541 (1.3%)36/541 (6.7%)
Pioglitazone—5/392 (1.3%)35/392 (8.9%)
Rosiglitazone—2/399 (0.5%)21/399 (5.3%)
Vitamin D Placebo—2/614 (0.3%)—
Vitamin D—9/607 (1.5%)—
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventPlaceboPioglitazoneRosiglitazoneVitamin D PlaceboVitamin D
HypoglycemiaMetabolism and nutrition disorders0/5411/3921/3990/6142/607
Benign prostatic hyperplasiaReproductive system and breast disorders0/5411/3920/3990/6141/607
Bronchial disorderRespiratory, thoracic and mediastinal disorders0/5411/3920/3991/6140/607
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/5411/3920/3990/6141/607
Renal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/5411/3920/3990/6140/607
Cholecystitis acuteHepatobiliary disorders0/5410/3921/3990/6140/607
AngioplastySurgical and medical procedures1/5410/3920/3990/6141/607
Aortic aneurysmVascular disorders1/5410/3920/3990/6140/607
Aortic aneurysm repairSurgical and medical procedures1/5410/3920/3991/6140/607
Chronic sinusitisInfections and infestations1/5410/3920/3990/6141/607
Most frequent other events
Showing 10 of 74
Most frequent other events
EventPlaceboPioglitazoneRosiglitazoneVitamin D PlaceboVitamin D
Edema peripheralGeneral disorders4/5418/3921/399——
EdemaGeneral disorders2/5415/3921/399——
DyspneaRespiratory, thoracic and mediastinal disorders1/5413/3924/399——
ConstipationGastrointestinal disorders0/5413/3921/399——
DiarrheaGastrointestinal disorders2/5413/3921/399——
MalaiseGeneral disorders1/5413/3920/399——
Cardiac failureCardiac disorders3/5412/3920/399——
Abdominal pain upperGastrointestinal disorders0/5412/3920/399——
DyspepsiaGastrointestinal disorders1/5412/3920/399——
NauseaGastrointestinal disorders2/5412/3920/399——

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboPioglitazone (PIO)Rosiglitazone (RSG)Total
Mean66.4 ± 6.866.3 ± 6.666.5 ± 6.466.4 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPioglitazone (PIO)Rosiglitazone (RSG)Total
Female220167161548
Male321225238784
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboPioglitazone (PIO)Rosiglitazone (RSG)Total
European/ Caucasian/ White330241255826
Unknown533435122
South Asian634648157
Black African453526106
Native South American33262483
Other Asian106622
Native North American1247
Japanese1012
Arab/ Persian1102
Native Hawaiian/ Australian or Other Asian Pacific1102
Malays1001
Sub-Saharan African1001
Missing1001
08

Study locations

331 sites
  • GSK Investigational Site
    Long Beach, California 90822, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Northridge, California 91324, United States
  • GSK Investigational Site
    San Diego, California 92109, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Tucker, Georgia 30084, United States
  • GSK Investigational Site
    Pocatella, Idaho 83209, United States
  • GSK Investigational Site
    Pocatello, Idaho 83201, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70112, United States
  • GSK Investigational Site
    Haverhill, Massachusetts 1830, United States
  • GSK Investigational Site
    Minneapolis, Minnesota 55454, United States
  • GSK Investigational Site
    St. Louis, Missouri 63106, United States
  • GSK Investigational Site
    Kalispell, Montana 59901, United States
  • GSK Investigational Site
    Westfield, New York 14787, United States
  • GSK Investigational Site
    Durham, North Carolina 27710, United States
  • GSK Investigational Site
    Cleveland, Ohio 44195, United States
  • GSK Investigational Site
    Portland, Oregon 97216, United States
  • GSK Investigational Site
    Portland, Oregon 97239, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Memphis, Tennessee 38104, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Houston, Texas 77030, United States
  • GSK Investigational Site
    Temple, Texas 76508, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires 1090, Argentina
  • GSK Investigational Site
    Coronel Suarez, Buenos Aires, Argentina
  • GSK Investigational Site
    Mar del Plata, Buenos Aires 7600, Argentina
  • GSK Investigational Site
    San Nicolas, Buenos Aires B2900DMH, Argentina
  • GSK Investigational Site
    Buenos Aires, 1405, Argentina
  • GSK Investigational Site
    Salta, 4400, Argentina
  • GSK Investigational Site
    San Miguel de Tucuman, 4000, Argentina
  • GSK Investigational Site
    Zárate, B2800DGH, Argentina
  • GSK Investigational Site
    Calgary, Alberta T2T 5C7, Canada
  • GSK Investigational Site
    Calgary, Alberta T3S OM3, Canada
  • GSK Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • GSK Investigational Site
    Surrey, British Columbia V3R 3P1, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V6H 3X8, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R2H 0R8, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R2V 4W3, Canada
  • GSK Investigational Site
    Winnipeg, Manitoba R3E 3P4, Canada
  • GSK Investigational Site
    Saint John's, Newfoundland and Labrador A1B 3V6, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3H 2Y9, Canada
  • GSK Investigational Site
    Barrie, Ontario L4M 7G1, Canada
  • GSK Investigational Site
    Brampton, Ontario L6Z 4N5, Canada
  • GSK Investigational Site
    Cambridge, Ontario N1R 7L6, Canada
  • GSK Investigational Site
    Hamilton., Ontario L8N 3X5, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8L 2X2, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8N 3Z5, Canada
  • GSK Investigational Site
    London, Ontario N6A 4V2, Canada
  • GSK Investigational Site
    Mississauga, Ontario L5M 2V8, Canada
  • GSK Investigational Site
    Ohsweken, Ontario N0A 1M0, Canada
  • GSK Investigational Site
    Oshawa, Ontario L1J 2K1, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1C 1S6, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 1A2, Canada
  • GSK Investigational Site
    Thornhill, Ontario L4J 8L7, Canada
  • GSK Investigational Site
    Toronto, Ontario M4R 2G4, Canada
  • GSK Investigational Site
    Toronto, Ontario M5C 2T2, Canada
  • GSK Investigational Site
    Toronto, Ontario M9L 1W9, Canada
  • GSK Investigational Site
    Laval, Quebec H7T 2P5, Canada
  • GSK Investigational Site
    Montreal, Quebec H2W 1R7, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1J 1Z6, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1L 3L5, Canada
  • GSK Investigational Site
    Quebec City, Quebec G1V 4G5, Canada
  • GSK Investigational Site
    Rimouski, Quebec G5L 5T1, Canada
  • GSK Investigational Site
    Saint-Georges, Quebec G5Y 4T8, Canada
  • GSK Investigational Site
    Sainte-Foy, Quebec G1V 4G2, Canada
  • GSK Investigational Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • GSK Investigational Site
    Temuco, Región De La Araucania, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8330024, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago 8331143, Chile
  • GSK Investigational Site
    Santiago, Región Metro De Santiago, Chile
  • GSK Investigational Site
    Osorno, Chile
  • GSK Investigational Site
    Valdivia, Chile
  • GSK Investigational Site
    Victoria, Chile
  • GSK Investigational Site
    Armenia, Colombia
  • GSK Investigational Site
    Barrangquilla, Colombia
  • GSK Investigational Site
    Barranquilla, Colombia
  • GSK Investigational Site
    Bogotac, 83012, Colombia
  • GSK Investigational Site
    Bogota, Colombia
  • GSK Investigational Site
    Cali, Colombia
  • GSK Investigational Site
    Cartagena, 71 31-315, Colombia
  • GSK Investigational Site
    Cartagena, Colombia
  • GSK Investigational Site
    Espinal, Colombia
  • GSK Investigational Site
    Floridablanca, Colombia
  • GSK Investigational Site
    Manizales, Colombia
  • GSK Investigational Site
    Medellín, Colombia
  • GSK Investigational Site
    Pereira, Colombia
  • GSK Investigational Site
    Havirov, 736 01, Czech Republic
  • GSK Investigational Site
    Jihlava, 586 01, Czech Republic
  • GSK Investigational Site
    Mestec Kralove, 289 03, Czech Republic
  • GSK Investigational Site
    Ostrava, 70030, Czech Republic
  • GSK Investigational Site
    Prague, 181 00, Czech Republic
  • GSK Investigational Site
    Praha 4, 140 21, Czech Republic
  • GSK Investigational Site
    Praha 5, 150 00, Czech Republic
  • GSK Investigational Site
    Praha 5, 158 00, Czech Republic
  • GSK Investigational Site
    Praha 6, 160 00, Czech Republic
  • GSK Investigational Site
    Praha, 102 00, Czech Republic
  • GSK Investigational Site
    Pribram 8, 261 01, Czech Republic
  • GSK Investigational Site
    Rakovnik, 269 01, Czech Republic
  • GSK Investigational Site
    Uherske Hradiste, 68601, Czech Republic
  • GSK Investigational Site
    Aarhus-N, 8200, Denmark

Showing the first 100 of 331 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Punthakee Z, Bosch J, Gerstein HC. Setting the record straight on TIDE: a lost opportunity for patients with diabetes. Diabetologia. 2013 Sep;56(9):1884-7. doi: 10.1007/s00125-013-2959-0. Epub 2013 Jun 6. PubMed 23740195 ↗
  • Punthakee Z, Bosch J, Dagenais G, Diaz R, Holman R, Probstfield J, Ramachandran A, Riddle M, Ryden LE, Zinman B, Afzal R, Yusuf S, Gerstein H; TIDE Trial Investigators. Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia. 2012 Jan;55(1):36-45. doi: 10.1007/s00125-011-2357-4. Epub 2011 Oct 29. PubMed 22038523 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2009
First posted
Apr 13, 2009
Start
May 2009
Primary completionActual
Nov 2010
CompletionActual
Nov 2010
Results first posted
Dec 13, 2011
Last update
Apr 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00879970
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 13, 2009
Start date
May 2009
Primary completion
Nov 2010
Completion
Nov 2010
Results posted
Dec 13, 2011
Last update
Apr 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pioglitazone · Rosiglitazone · Vitamin D

Start the discussion